Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
FLOVENT DISKUS 100 is a inhaled corticosteroid containing fluticasone propionate in dry powder form, approved in 2000 for asthma and COPD maintenance therapy. It works by reducing airway inflammation and bronchial hyperresponsiveness in patients with persistent respiratory disease. This small-molecule steroid is a foundational therapy in respiratory disease management.
Product is approaching loss of exclusivity with moderate competitive pressure (60/100), signaling potential team contraction and transition focus to newer pipeline assets.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on FLOVENT DISKUS as it approaches LOE offers limited growth potential but provides solid experience in mature product management, generic transition strategy, and competitive positioning in a crowded therapeutic class. This role is best suited for professionals seeking stability in a legacy franchise or those transitioning to newer pipeline assets within GSK.
Worked on FLOVENT DISKUS 100 at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.